Abstract
Background: Mitigation of unwanted effects is a major issue to be addressed in drug discovery. The human genome shares a considerable degree of sequence identity and structural homology whereby multiple binding pockets of similar composition is seen across different family of proteins. This distribution of similar binding pockets in different proteins is a major reason for cross reactivity upon ligand binding. Therefore, identifying such off-targets on a case-to-case basis in the early stages of drug discovery pipeline is very much essential. Especially for developing specific ligands against isozymes such as glycogen phosphorylase it is a pre-requisite owing to its implications. The inhibitors of glycogen phosphorylase (GPi) control the blood glucose level effectively by inhibiting the hepatic GP (hGP). But due to its high degree of sequence identity with the muscle form (mGP) and similar binding pocket, these ligands cross react resulting in impaired muscle function due to prolonged relaxation. Therefore, molecular targeting or optimizing the lead to a specific target (hGP) is very essential. In the current work, a comparative docking approach was adopted wherein suitable ligands were designed based on the chemical descriptors present in lig18 binding site of mGP and hGP followed by virtual docking.
Results: The docking results showed that lig18 optimized compound (lig18_7) had better affinity to hGP and mGP respectively. lig18_7 interacted with residues Arg171 and Asn172 that are present specifically in hGP indicating specificity. Using this improved comparative docking approach isoform- specific ligands can be effectively developed.Keywords: Comparative docking, Glycogen phosphorylase, Glycogen phosphorylase inhibitors, Pentacyclic triterpenes, Cross reactivity.
Current Topics in Medicinal Chemistry
Title:An Improved Comparative Docking Approach for Developing Specific Glycogen Phosphorylase Inhibitors Using Pentacyclic Triterpenes
Volume: 17 Issue: 14
Author(s): V. Badireenath Konkimalla*
Affiliation:
- School of Biological Sciences, National Institute of Science Education and Research (NISER), POBhimpur- Padanpur, Via- Jatni, Khurda – 752050,India
Keywords: Comparative docking, Glycogen phosphorylase, Glycogen phosphorylase inhibitors, Pentacyclic triterpenes, Cross reactivity.
Abstract: Background: Mitigation of unwanted effects is a major issue to be addressed in drug discovery. The human genome shares a considerable degree of sequence identity and structural homology whereby multiple binding pockets of similar composition is seen across different family of proteins. This distribution of similar binding pockets in different proteins is a major reason for cross reactivity upon ligand binding. Therefore, identifying such off-targets on a case-to-case basis in the early stages of drug discovery pipeline is very much essential. Especially for developing specific ligands against isozymes such as glycogen phosphorylase it is a pre-requisite owing to its implications. The inhibitors of glycogen phosphorylase (GPi) control the blood glucose level effectively by inhibiting the hepatic GP (hGP). But due to its high degree of sequence identity with the muscle form (mGP) and similar binding pocket, these ligands cross react resulting in impaired muscle function due to prolonged relaxation. Therefore, molecular targeting or optimizing the lead to a specific target (hGP) is very essential. In the current work, a comparative docking approach was adopted wherein suitable ligands were designed based on the chemical descriptors present in lig18 binding site of mGP and hGP followed by virtual docking.
Results: The docking results showed that lig18 optimized compound (lig18_7) had better affinity to hGP and mGP respectively. lig18_7 interacted with residues Arg171 and Asn172 that are present specifically in hGP indicating specificity. Using this improved comparative docking approach isoform- specific ligands can be effectively developed.Export Options
About this article
Cite this article as:
Konkimalla Badireenath V.*, An Improved Comparative Docking Approach for Developing Specific Glycogen Phosphorylase Inhibitors Using Pentacyclic Triterpenes, Current Topics in Medicinal Chemistry 2017; 17 (14) . https://dx.doi.org/10.2174/1568026617666161104110045
DOI https://dx.doi.org/10.2174/1568026617666161104110045 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials
Clinical Cancer Drugs Matrine: Bioactivities and Structural Modifications
Current Topics in Medicinal Chemistry Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design Mitophagy in Carcinogenesis and Tumour Progression- A New Paradigm with Emerging Importance
Anti-Cancer Agents in Medicinal Chemistry Antimicrobial Drug Interactions in the Critically Ill Patients
Current Clinical Pharmacology Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment
Current Cancer Drug Targets Immunomodulatory and Anti-inflammatory Properties of Artesunate in Experimental Colitis
Current Medicinal Chemistry Biocompatible Micelles Based on Squalene Portions Linked to PEGylated Polyaspartamide as Potential Colloidal Drug Carriers
Current Nanoscience Costimulation, Coinhibition and Cancer
Current Cancer Drug Targets Interactions of Curcumin and Its Derivatives with Nucleic Acids and their Implications
Mini-Reviews in Medicinal Chemistry Gastrin-Releasing Peptide Receptor as a Molecular Target for Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Sulfonyl Group-Containing Compounds in the Design of Potential Drugs for the Treatment of Diabetes and Its Complications
Current Medicinal Chemistry Immune Modulation by Ionizing Radiation and its Implications for Cancer Immunotherapy
Current Pharmaceutical Design An Emerging Therapeutic Approach by Targeting Myoferlin (MYOF) for Malignant Tumors
Current Topics in Medicinal Chemistry Carbohydrate based Potential Chemotherapeutic Agents: Recent Developments and their Scope in Future Drug Discovery
Mini-Reviews in Medicinal Chemistry Ghrelin and Cardiovascular Diseases
Current Cardiology Reviews Extracellular Superoxide and the Growth of Pancreatic Carcinoma
Current Cancer Therapy Reviews New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Aptamers in Targeted Nanotherapy
Current Topics in Medicinal Chemistry